Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 60

Liposomal bupivacaine plus bupivacaine versus ropivacaine for PENG block in hip replacement

Official title: Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty: a Prospective, Randomized, Single Blind, Active Controlled Study

Run by Huazhong University of Science and Technology · NCT06565910 · Data updated 2026-11-12

This trial will test whether adding liposomal bupivacaine to regular bupivacaine for a pericapsular nerve group (PENG) block gives longer and better pain relief than ropivacaine after hip replacement surgery.

More Hip Fractures trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment60 (estimated)
SponsorHuazhong University of Science and Technology
Academic / other
Locations1 site (Wuhan, Hubei)
StatusRecruiting
StartedDecember 4, 2024
Main results expectedJune 1, 2026
Study endsJuly 1, 2026
Registry record updatedMarch 13, 2026
Trial IDNCT06565910 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults having hip arthroplasty for hip fracture who are ASA physical status I–II, have normal coagulation, and have no allergy to amide local anesthetics are the intended participants.

Probably not a fit

Patients with severe systemic disease (ASA III or higher), abnormal coagulation, or an allergy to amide local anesthetics would not be eligible and are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, phase 4 interventional trial enrolling patients undergoing hip arthroplasty for hip fracture who meet ASA I–II and normal coagulation criteria. Participants receive a PENG block and are assigned to receive either liposomal bupivacaine plus standard bupivacaine or ropivacaine. The study compares pain relief duration, overall analgesic efficacy, opioid consumption, patient satisfaction, and records adverse events to assess safety. Outcomes are measured in the immediate postoperative period and during standard postoperative follow-up.

Why it matters

Potential benefit: If successful, this approach could provide longer-lasting pain relief after hip replacement and reduce the need for opioid medications.

How similar studies have gone: Liposomal bupivacaine has produced longer analgesia in some wound infiltration and peripheral block studies, but results are mixed and specific evidence for PENG block remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* American Society of Anesthesiologists(ASA) I\~II
* Normal coagulation
* Clinical diagnosis of hip fracture

Exclusion Criteria:

* Presence of severe systemic diseases or ASA grade III or higher
* Allergy to amide local anesthetics

Where it's running

  • Department of Anesthesiology, Tongji Hospital, Tongji Medical College, HUST
    Wuhan, Hubei, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.